- Stable Supply of Essential Medicines through Contract Manufacturing Before Completion of Indonesian 바카라 카지노-Derived Medicinal Products Plant
- Training of Bio-Specialists at Andong Plant in Preparation for Indonesian Commercial Production in 2026
[by Yu, Suin] SK Plasma, currently building a plasma fractionation plant in Indonesia, is set to commence its Plasma-Derived Medicinal Products (PDMPs) CMO (Contract Manufacturing Organization) business in the country.
On April 10, SK 바카라 카지노 announced that Indonesian 바카라 카지노 intended for CMO use has arrived at its Andong plant for 바카라 카지노 fractionation production.
This 바카라 카지노 import is part of a project initiated in 2023 to establish production facilities for PDMPs self-sufficiency in Indonesia. Until the new plant is completed, SK 바카라 카지노 will supply PDMPs, which are essential medicines, in the form of CMO.
This marks the first time 바카라 카지노 collected from Indonesian citizens has been imported into Korea to help ensure a stable PDMP supply.
Starting with this first 바카라 카지노 import, the sequentially arriving Indonesian 바카라 카지노 will be fully utilized in production in the first half of this year. Until the local fractionation plant is completed, the Indonesian health authorities will send 바카라 카지노 secured through their national blood sources to SK 바카라 카지노, which will produce two finished products, 'Albumin' and 'Immunoglobulin,' at the Andong plant and supply them to Indonesia.
Additionally, during the contract manufacturing period, technical transfer training for local Indonesian personnel will be conducted at the Andong plant.
The company plans to provide specialized technical education in various fields, such as quality control and production to local personnel, fostering them into bio-specialists capable of stable production, and management of pharmaceuticals after the plant's completion.
This Indonesian 바카라 카지노 import follows the CMO contract with Singapore, marking the second such case. SK 바카라 카지노 was the first Asian company to be selected as a contract manufacturing business in the national PDMPs tender, previously monopolized by multinational pharmaceutical companies, and has been supplying PDMPs to Singapore since 2023.
CEO Seung-Joo Kim of SK 바카라 카지노 stated, "Given the nature of blood-based pharmaceuticals, it is recommended to produce medicines using the 바카라 카지노 of the country's citizens. However, the high level of technology and infrastructure required for PDMP production makes the market potential for CMO very high. Based on SK 바카라 카지노's technology and solutions, including CMO and local technology transfer, we plan to gradually expand our global business through collaboration with countries that need production technology."
Meanwhile, in 2023, SK 바카라 카지노 established a joint venture, SK 바카라 카지노 Core, with the Indonesia Investment Authority (INA) to build 바카라 카지노 infrastructure in Indonesia. The company is constructing a PDMPs production plant capable of fractionating 600,000 liters of 바카라 카지노 annually in the Karawang International Industrial City in Jakarta. The plant is scheduled to be operational in the fourth quarter of 2026.